West Pharmaceutical Services, Inc.

NYSE:WST

Medical - Instruments & Supplies

Healthcare
$404.02 +1.56%

+$5.04 today

Market cap
$28.14B
Beta
1.18
P/E (TTM)
43.6
EPS (TTM)
$7.54
Dividend yield
0.26%
52W Low $206.80High $336.82

Volume 0.59M

Average 0.85M

WST Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

West Pharmaceutical Services, Inc.NYSE: WST

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures declines year over year

Q2 FY2026 capital expenditures of $43.2M (cash outflow) fell 42.6% year over year, behind the -32.3% change in trailing-twelve-month capital expenditures. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.

Context

  • Capital expenditures amounted to 9.3% of revenue in FY2025, down 3.7 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -42.6% toward the trailing-twelve-month pace of -32.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$43.2M+1.2% QoQ
Last fiscal yearDec 2025
-$285.9M-24.2% YoY
LTMJun 2026
-$225.3M-32.3% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.6%——
1 year-24.2%——
3-year CAGR+0.2%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(285.9M) USD
Year-over-year change
+24.2%

Capital Expenditures vs competitors

How WST compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -32.3% is the 4th highest of 5, against a peer median of +3.4%.
  • Capital expenditures amounts to 6.8% of revenue for WST, versus a peer median of 13.3%.
WST Competitors
Capital Expenditures for WST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATRAptarGroup, Inc.LTM Jun 2026$273.09M USD-0.6%-5.0%6.9%
STVNStevanato Group S.p.A.LTM Jun 2026€272.65M EUR-38.5%+1.4%22.3%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$225.3M USD-32.3%+0.2%6.8%
ICUIICU Medical, Inc.LTM Jun 2026$83.54M USD+7.4%-3.9%3.9%
BLFSBioLife Solutions, Inc.LTM Mar 2026$19.69M USD+488.5%-3.0%19.7%
Peer median (excluding WST) —+3.4%-3.5%13.3%

Competitors are the stored peer set for WST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income661.8M585.9M593.4M492.7M493.7M
Depreciation & Amortization122.3M120.6M137.3M155.4M171.4M
Deferred Income Tax(42.9M)(30.8M)37.5M0(13.7M)
Stock-Based Compensation37.5M23.7M23.3M18.7M23.8M
Change in Working Capital(193.8M)(15M)(20.4M)2.9M79.8M
Accounts Receivables(123.5M)(35.6M)4M(58.8M)6.9M
Inventory(86.5M)(49.8M)(13.5M)42M(62.8M)
Accounts Payables16.8M(2.8M)4.4M2.9M17.9M
Other Working Capital(600K)73.2M(15.3M)16.8M117.8M
Other Non-Cash Items(900K)36.1M5.4M(16.3M)(200K)
Operating Cash Flow584M724M776.5M653.4M754.8M
Capital Expenditures(253.4M)(284.6M)(362M)(377M)(285.9M)
Acquisitions (Net)(2.2M)0000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities2.5M(3.6M)(6.7M)(1.7M)0
Investing Cash Flow(253.1M)(288.2M)(368.7M)(378.7M)(285.9M)
Debt Repayment(2.2M)(44.3M)(2.3M)(27.6M)(1.1M)
Common Stock Issued000018.2M
Common Stock Repurchased(151.9M)(222.2M)(451.2M)(566.6M)(134M)
Dividends Paid(51.1M)(54.1M)(57M)(59.1M)(61.2M)
Other Financing Activities37.1M27M50.9M30.7M(7M)
Financing Cash Flow(168.1M)(293.6M)(459.6M)(622.6M)(185.1M)
Effect of Forex Changes(15.7M)(10.5M)11.4M(21.4M)22.9M
Net Change in Cash147.1M131.7M(40.4M)(369.3M)306.7M
Free Cash Flow330.6M439.4M414.5M276.4M468.9M

West Pharmaceutical Services, Inc.

NYSE:WST

Intrinsic Alpha fair value

Locked

Current Price

$404.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.